Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE-TNK: Tenecteplase bridging vs EVT alone in stroke
NCT04733742Phase 3Completed
- Sponsor
- Xinqiao Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by Xinqiao Hospital. Started May 2022; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04733742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733742.